![Mechanism of steroid hormone action.\
In the absence of hormone, steroid receptor monomers (SR) are associated with heat shock protein complexes (HSP) and are typically basally phosphorylated. Upon binding hormone, receptors dissociate from heat shock proteins, dimerize, bind to target gene-specific sites containing hormone response elements (HRE), and recruit a series of coactivator complexes to regulate target gene transcription. Site-specific phosphorylation of receptors increases subsequent to hormone binding, with some increases occurring rapidly, and others with delayed kinetics. Upon steroid binding, some receptors also interact with Src and MNAR, activating Src and downstream kinases including p42/p44 MAPK. Membrane-associated receptors (mSR) also bind hormone and initiate signaling cascades. While some of these are classical steroid receptors, others bear no homology to the steroid receptor superfamily.](nrs05005.f1){#fig1}

![Domain structures of steroid receptors.\
The numbers of the amino acids found at the boundaries in the individual receptors between the NTD (amino-terminal domain), DBD (DNA binding domain), hinge region (H), and ligand binding domain (LBD) are indicated in the figure. Also shown are the best characterized phosphorylation sites in the human steroid receptors.](nrs05005.f2){#fig2}

Introduction
============

Steroid hormone receptors are hormone-activated transcription factors whose activities are also modulated by posttranslational modifications including phosphorylation \[[@r37]\]. In the absence of hormone, receptor monomers associate with heat shock protein complexes and as a rule are minimally phosphorylated ([Figure 1](#fig1){ref-type="fig"}). Upon binding hormone, the receptors dimerize, cytoplasmic receptors translocate to the nucleus and the receptors bind to sequence-specific hormone response elements (HRE). Typically, hormone binding and localization to specific DNA binding sites is accompanied by an increase in receptor phosphorylation. The receptors recruit a series of coactivator complexes that facilitate chromatin remodeling, recruitment of Pol II (polymerase II), and transcription of specific target genes. Phosphorylation of coactivators and Pol II is also integral to regulation of transcription. Moreover, some of the proteins recruited to the chromatin by steroid receptors are themselves kinases that can modify histones or other proteins associated with chromatin.

In some cases, upon hormone binding, a portion of the cytoplasmic receptor associates with and activates Src kinase, leading to activation of downstream signaling \[[@r34]; [@r60]\]. In addition, there is evidence that a small fraction of some of the receptors is associated with the cell membrane and hormone binding induces activation of a variety of signaling pathways.

Structurally, the steroid receptors share many common features \[[@r35]\], as shown in [Figure 2](#fig2){ref-type="fig"}. The receptors all contain carboxyl terminal ligand binding domains (LBD) that include a region termed activation function 2 (AF-2), which is a site for coactivator binding and thus is important for the induction of transcriptional activity. The LBD is linked to the DNA binding domain (DBD) by a hinge region (H) that contains a nuclear localization signal. The DNA binding domains are the most highly conserved regions of the receptors and each contains two Zn^++^ binding motifs. The amino terminal domains (NTD) are the least conserved regions both in sequence and in length, but all contain at least one region, termed AF-1 (activation function 1), that is required for optimal transcriptional activity. Most of the phosphorylation sites identified in steroid receptors are located in the NTDs of the receptors, although many have at least one phosphorylation site in the hinge region, and there are limited reports of phosphorylation sites in the hormone and DNA binding domains. Shown in [Figure 2](#fig2){ref-type="fig"} are the best characterized phosphorylation sites in the human steroid receptors. Others have been proposed based on *in vitro* studies and additional sites have been identified in steroid receptors from other species. Consequently, there are likely to be additional unidentified sites in at least some of the human steroid receptors.

Several strategies have been used to elucidate the roles of cell signaling in steroid receptor action and in crosstalk between steroid receptors and growth factor signaling pathways. The first is simply to alter the activity of a signaling pathway using activators or inhibitors and to measure the effect on steroid receptor activity. Changes identified using this technique demonstrate a role for the pathway in regulating receptor action, but the target may be an associated protein rather than the receptor, or a combination of the receptor and other proteins. A second approach is to measure the activity of receptors containing alanine substitutions for one or more of the serine or threonine phosphorylation sites. This strategy requires knowledge of the location of the phosphorylation sites. While many have been located, others have yet to be identified. Finally, a number of studies in recent years implicate steroid receptors in the direct activation of cell signaling pathways potentially modifying receptor function, as well as inducing activation of target genes sensitive to increased kinase activity.

Modulation of cell signaling pathways alters steroid receptor activity
======================================================================

Ligand-independent activation
-----------------------------

The most striking evidence for the potential importance of cell signaling in steroid receptor action was the finding that some steroid receptors can be activated in the absence of measurable levels of hormones by treatments that enhance activity of kinases or inhibit phosphatase activities. Denner et al. first showed that 8-Br cAMP treatment of cells transfected with a chicken progesterone receptor (cPR) expression vector and a PR-responsive reporter caused hormone-independent, but cPR-dependent, activation of the reporter \[[@r31]\]. This activation was independent of the four characterized phosphorylation sites in cPR and 8-Br cAMP did not induce phosphorylation of PR \[[@r9]\]. However, subsequent studies revealed that 8-Br cAMP caused activation of p42/p44 MAPK (mitogen-activated kinase) and increased phosphorylation of the p160 coactivator, SRC-1 (steroid receptor coactivator-1); these SRC-1 phosphorylation sites contributed to the ligand-independent activation \[[@r92]\]. Other signaling pathways also induce activity. Treatment of transiently transfected cells with dopamine activates a number of receptors including cPR \[[@r85]\] and ERα (estrogen receptor α) \[[@r98]\] in the absence of their cognate ligands. Treatment with the phosphatase inhibitor, okadaic acid, also induces ligand-independent activation of cPR \[[@r31]\]. There is evidence that these alternate activation pathways are also functional *in vivo*. For example, treatment with dopamine causes PR-dependent induction of lordosis in female rats and mice \[[@r6]; [@r68]; [@r69]; [@r70]\]. As expected for a PR-dependent response, PR null mice are not responsive.

### Estrogen receptor α

The responsiveness of receptors to cell signaling pathways in the absence of hormone differs greatly. Whereas the glucocorticoid receptor (GR) requires ligand for activation, ERα is very responsive to cell signaling pathways. Indeed, ERα in cells maintained in phenol red-free, charcoal-stripped serum, utilized to minimize/eliminate steroids, frequently displays substantial basal transcriptional activity in the absence of added ligand; this activity can be reduced by the use of a pure anti-estrogen such as ICI 182780, showing that the activity is dependent upon ERα \[[@r98]\]. There are multiple pathways for hormone-independent activation of ERα. One of the best characterized of the hormone-independent pathways for the activation of the ERα is the EGF (epidermal growth factor)-dependent activation of human ERα in transfected HeLa cells. EGF-dependent activation induces phosphorylation of Ser^118^ in the amino terminus of ER \[[@r55]\]. Substitution of an alanine for the serine abrogates the hormone-independent activation. However, substitution of a glutamic acid, which provides a constitutive negative charge, restores responsiveness to EGF, but does not cause the receptor to become constitutively active \[[@r16]\]. Thus, EGF-dependent activation requires phosphorylation of ERα at Ser^118^, as well as phosphorylation of at least one other target. One possibility is Ser^167^ in ERα. EGF treatment typically results in activation of Rsk downstream of p42/p44 MAPK; Ser^167^ is a substrate for Rsk \[[@r24]; [@r53]\]. Other pathways are independent of Ser^118^ phosphorylation (or the corresponding mouser Ser^122^), demonstrating that there are multiple means of activating ER independent of its ligand \[[@r82]\].

### Androgen receptor

The androgen receptor (AR) also has the capacity to respond to cell signaling pathways in cells grown in medium depleted of hormone. Among the factors reported to induce AR activity are EGF, KGF (keratinocyte growth factor) \[[@r28]\], IL-6 (interleukin-6) \[[@r50]\], and forskolin \[[@r80]\], an activator of protein kinase A. Overexpression of the EGF receptor family member, HER2 (Human Epidermal Growth Factor Receptor 2), also induces AR activity \[[@r26]\]. Activation of AR by cell signaling pathways in the absence of normal levels of androgens likely contributes to the recurrence of prostate cancer. The recurrent tumors express high levels of AR and re-express many AR target genes including PSA (prostate specific antigen) (reviewed in \[[@r3]\]). Several investigators have demonstrated that AR-positive, androgen-independent cell lines that express PSA in medium depleted of androgens still require AR for cell growth and expression of PSA \[[@r2]; [@r116]\]. Because the AR sequence does not differ from that of AR in androgen-dependent cells, it is presumed that altered cell signaling is causing aberrant receptor activation.

Potentiation of partial antagonist activity
-------------------------------------------

Although some receptors show minimal responsiveness to cell signaling pathways in the absence of ligand, enhanced cell signaling often potentiates receptor activity in the presence of a partial antagonist. Treatment with 8-Br cAMP causes the mammalian PR and GR antagonist, RU486 (mifepristone), to act as a GR \[[@r81]\] and a PR-B isoform \[[@r13]; [@r95]\] specific agonist. The finding that cell signaling pathways can induce hormone-independent activation, can cause receptors to be responsive to lower levels of hormone, and can cause antagonists such as tamoxifen and RU486 to have agonist activity, is particularly relevant in hormone-sensitive cancers such as breast and prostate cancer. Signaling pathways that enhance AR activity are often activated in advanced prostate cancers \[[@r45]; [@r46]; [@r47]; [@r73]\] and HER2 signaling combined with overexpression of AIB1 is one contributor to tamoxifen resistance in breast cancer \[[@r97]\].

Modulation of agonist-dependent activity
----------------------------------------

The activities of specific kinases are also required for hormone-dependent activation of steroid receptors, although in many cases the targets of receptor action have not been fully elucidated. This is an active area of research and the studies are far from comprehensive. The response of receptors to signaling pathways can be cell-specific and it is likely that many of the responses will also be target gene-specific. Although there are some recent studies examining regulation of endogenous genes, most of the information has been obtained using transfected reporters. Whereas cyclin-dependent kinases generally enhance the activity of steroid receptors, the actions of other kinases are receptor-specific. Surprisingly, some of the cyclins function as receptor coactivators or corepressors independent of their partner kinases. Only those actions that require kinase activity are discussed below. Signaling pathways that induce hormone-independent action or cause antagonist/agonist switches also potentiate the corresponding hormone-dependent activity and have been discussed above.

### Human progesterone receptor

Human PR requires Cdk2 (cyclin-dependent kinase 2) for hormone-dependent activation of at least some of its target genes \[[@r78]\]. Inhibition of Cdk activity with the cyclin-dependent kinase inhibitor roscovitine blocks hormone-dependent induction of a PR-responsive reporter or of the endogenous metallothionein gene; reducing expression of Cdk2 also strongly inhibits PR activity. The Cdk2 partner, cyclin A~2~, is a PR coactivator that depends on binding Cdk for its potentiation of PR activity. Although PR can be phosphorylated by cyclin A~2~/Cdk2 *in vitro* \[[@r56]\], the potentiation of PR activity is independent of PR phosphorylation \[[@r78]\]. Rather, the target is likely to be the p160 coactivator, SRC-1. In ChIP (chromatin immunoprecipitation assays), roscovitine treatment has no effect on the binding of either PR or cyclin A to an MMTV (mouse mammary tumor-like virus) promoter, but it prevents the hormone-dependent recruitment of SRC-1 \[[@r78]\]. Consistent with the idea that cyclin A/Cdk2 is important for PR function, PR-dependent activation of the MMTV promoter is cell cycle-dependent \[[@r79]\]. PR activity is highest in S phase, where cyclin A is most highly expressed, and lower in early G1 or in G2/M phase. In cells with low levels of the cyclin-dependent kinase inhibitor, p27, overexpression of activated Cdk2 induces hormone-independent activation of PR and this hormone-independent activation is blocked by mutation of Ser^400^, a PR phosphorylation site \[[@r83]\].

Other kinases and phosphatases also modulate PR action, although their targets have not been elucidated. Treatment with EGF, resulting in activation of p42/p44 MAPK, enhances hormone-dependent activity \[[@r29]\]. In contrast, activation of p38 MAPK by MKK6 inhibits PR activity \[[@r86]\]. Phosphatases also potentiate PR activity. The PP1 and PP2A inhibitor, okadaic acid, stimulates PR activity \[[@r12]\]. In contrast, overexpression of the phosphatase, PPM1D (p53-induced serine/threonine phosphatase, protein phosphatase 1D magnesium-dependent, delta isoform), enhances PR activity; reducing expression of endogenous PPM1D in MCF7 breast cancer cells inhibits PR activity \[[@r86]\].

### ERα and ERβ

Estrogen receptor activity is also modulated by cyclin A/Cdk2, but the activity is dependent upon the ability of the kinase to phosphorylate ERα \[[@r90]\]. Signaling pathways that induce hormone-independent activation also potentiate hormone-dependent actions. There are additional reports of kinases regulating ER activity in specific cell types. In contrast to its effects on PR, activation of p38 MAPK enhances the activity of ERα and increases its nuclear localization in endometrial cells \[[@r63]\]. However, p38 MAPK has been reported to play a role in ERBB2/ERBB3-dependent inhibition of ERβ (estrogen receptor β) activity \[[@r99]\]. GSK3β (glycogen synthase 3β) enhances ERα activity in neuronal cells \[[@r74]\]. Phosphatases also play a role in regulating activity. Overexpression of PP5 (protein phosphatase 5) reduces Ser^118^ phosphorylation in ERα and transcriptional activation. Moreover, reducing expression of PP5 enhances the transcriptional activity of ERα \[[@r51]\].

### Glucocorticoid receptor

Studies of GR show that cyclin-dependent kinases, Cdk1 and Cdk2, can phosphorylate GR *in vitro* and that GR expressed in yeast lacking the corresponding kinase activity is less active than in a wild type strain \[[@r58]\]. In contrast, a number of kinases inhibit GR activity. JNK (Jun N terminal kinase) inhibits rat GR activity through direct phosphorylation of GR \[[@r89]\]. Similarly, GSK3 inhibits rat GR through direct phosphorylation \[[@r91]\]; it has no effect on human GR, which lacks the corresponding phosphorylation site. Although p38 MAPK also inhibits GR activity, its effects are independent of the previously identified phosphorylation sites in GR \[[@r100]\]. Similar to ERα, PP5 is a negative regulator of GR activity \[[@r123]\].

### Androgen receptor

AR activity is also regulated by cyclin-dependent kinases. Similar to PR, overexpression of cyclin A enhances AR activity \[[@r78]\]. Roscovitine reduces AR activity and expression \[[@r21]\]. Although roscovitine inhibits many cyclin-dependent kinases, studies with more specific inhibitors suggest that Cdk1 is the kinase required for optimal AR protein expression. Consistent with a different cyclin-dependent kinase requirement compared to PR, the cell cycle dependence of AR activity exhibits a different pattern, with a decrease in activity at the G1/S boundary \[[@r71]\].

Cell signaling pathways regulate both the transcriptional activity and the stability of AR protein. Although inhibition of HER2 decreases AR protein levels and activity at low levels of hormone, the downstream kinase(s) responsible for regulating AR activity and expression has not been identified. HER2 activates Akt, but constitutively active Akt cannot compensate for inhibition of HER2 \[[@r73]\]. The role of Akt in AR action is controversial. Some investigators have found that Akt enhances AR activity, whereas others have reported that it inhibits AR activity \[[@r66]; [@r67]; [@r102]\]. Thus, actions of Akt are likely to be context-dependent. Akt inhibits the activity of GSK-3, a kinase that has been reported to inhibit AR activity \[[@r93]\]. Thus, in cells with high levels of GSK-3 activity, activation of Akt through inhibition of GSK-3 may increase AR activity. Mitogen-activated protein kinases (MAPK) also modulate AR activity. MEKK1, an upstream activator of p42/p44 MAPK, increases AR activity \[[@r1]\]. In contrast, inhibiting either JNK or p38 MAPK using siRNA for their upstream activators, MKK4 and MKK6, increases the expression of prostate specific antigen (PSA), an androgen-regulated gene in LNCaP prostate cancer cells \[[@r43]\].

### Steroid receptor coregulators

In addition to directly modifying the receptors, there is increasing evidence that receptor activities are regulated by changes in the phosphorylation state of coactivators and corepressors. For example, the p160 coactivators are extensively phosphorylated and are targets of multiple signaling pathways. Sites in SRC-1 are important in potentiating hormone-independent activities of chicken PR and human AR \[[@r92]; [@r105]\]. Phosphorylation of SRC-1 also plays a role in the interaction between human PR and SRC-1 \[[@r78]\]. The related p160 coactivator, TIF2 (transcription intermediary factor 2)/GRIP1 (glucocorticoid receptor interacting protein 1)/SRC-2, is phosphorylated by p42/p44 MAPK, and this phosphorylation plays a role in potentiating AR activity \[[@r46]\]. Phosphorylation of GRIP1 by p38 MAPK enhances its potentiation of ERα activity \[[@r39]\]. The third p160 coactivator, AIB1 (amplified in breast cancer 1)/SRC-3, plays a broader role in modulating the activities of multiple transcription factors. It is highly phosphorylated and different transcription factors, including steroid receptors, require phosphorylation of subsets of the phosphorylation sites for optimal potentiation of activity \[[@r112]; [@r113]\]. In some cases, the receptors themselves can alter phosphorylation of SRC-3. Estradiol treatment of ERα-containing cells increases the phosphorylation of SRC-3 at specific sites \[[@r120]\].

Phosphorylation of corepressors also influences their ability to repress transcription. Phosphorylation of the corepressor, SMRT (silencing mediator of retinoid and thyroid hormone receptors), by MEKK1 (MEK kinase 1), causes nuclear export, relieving repression \[[@r54]\]. MEKK1 also causes dissociation of N-CoR (nuclear receptor corepressor) complexes from androgen and estrogen receptors, enhancing transcriptional activity \[[@r122]\]. Other coregulators are also phosphoproteins and altered cell signaling is likely to influence association and activities of these proteins as well.

Kinases as coactivators
=======================

The responsiveness of steroid receptor function to a variety of cell signaling pathways suggests that there may be means to preferentially enhance or inhibit the phosphorylation of components of steroid receptor pathways in addition to the changes induced by global changes in kinase/phosphatase activities. The simplest mechanism would be direct interactions of receptors or coactivators with kinases or phosphatases, enhancing proximity to other potential substrates in the pathway. Indeed, one of the first candidate coactivators identified, TIF1α, is a protein kinase whose phosphorylation is enhanced upon interaction with activated nuclear receptors \[[@r38]\]. A novel nuclear protein kinase (ANPK) was identified as an AR-interacting protein that enhanced AR activity, but did not phosphorylate AR, leading to the conclusion that it acts through phosphorylation of AR coregulators or modification of chromatin proteins \[[@r75]\]. Other, better characterized kinases have also been found to be associated with nuclear receptors. AR interacts with Cdk9, a component of P-TEFb, a kinase that phosphorylates the CTD (carboxyl terminal domain) of Pol II, facilitating elongation of transcripts \[[@r62]\]. PR recruits cyclin A/Cdk2 to the promoter of target genes. Inhibition of its activity blocks transcription of an MMTV promoter and prevents recruitment of SRC-1, but not recruitment of another coactivator complex containing TRAP220 (thyroid receptor associated protein 220) \[[@r78]\]. Receptors also interact with phosphatases, thereby limiting activity. AR interacts with small carboxyl terminal domain phosphatase 2, which reduces the transcriptional activity of AR \[[@r103]\]. PP5 binds to ERα and ERβ; reducing PP5 expression enhances induction of a number of ERα target genes including c-myc and pS2 \[[@r51]\]. Other phosphatases and kinases are brought to receptor complexes by proteins that interact with receptors. For example, IκK (IκB kinase) associates with SRC-3, a substrate for the kinase; the kinase regulates the activity of the coactivator \[[@r112]\]. Kinase inhibitor studies show that Ser^118^ is at least in part phosphorylated by IκKα \[[@r110]\]. Thus, binding of SRC-3 to ERα may facilitate the hormone-dependent phosphorylation of Ser^118^. The phosphatase, PP5, interacts with GR through hsp90 complexes and reduces GR phosphorylation. Reducing expression of PP5 has target gene-specific effects on GR activity \[[@r106]\] ranging from no detectable effect to substantial inhibition of hormone-induced transcription.

Receptor phosphorylation
========================

Identification of phosphorylation sites
---------------------------------------

Early attempts to identify phosphorylation sites in steroid receptors relied on radiolabeling followed by direct protein sequencing or comparisons of the radiolabeling patterns of wild type and mutant receptors \[[@r14]; [@r32]; [@r64]; [@r117]; [@r119]; [@r121]\]. More recent approaches to the identification of sites have included mass spectrometry \[[@r44]; [@r56]\].

All of the steroid receptors contain multiple phosphorylation sites. The receptors are partially phosphorylated in the absence of hormone and are more highly phosphorylated after hormone treatment. Some of the sites exhibit enhanced phosphorylation in response to hormone, while phosphorylation of others is almost exclusively hormone-dependent. Most of the sites are serines or threonines in the amino terminal regions of the receptors, although there is a positionally-conserved Ser-Pro or Thr-Pro in the hinge regions of the steroid receptors. This site has been shown to be phosphorylated in chicken \[[@r32]\] and human PR \[[@r56]\], mouse ERα \[[@r59]\], and human AR \[[@r121]\]. Whether it is also phosphorylated in other receptors has not yet been determined. Most of these sites are located in Ser/Thr-Pro motifs, indicating that the receptors are direct targets of proline-directed kinases including the cyclin-dependent kinases and the MAPK family, which is consistent with studies showing that these kinases modulate receptor activity. Sites identified as authentic *in vivo* sites in the human steroid receptors are shown in [Figure 2](#fig2){ref-type="fig"}.

Some of the phosphorylation sites in steroid receptors are conserved across species, whereas others are unique to specific species. There is a GSK3β phosphorylation site in rat GR that is absent in human GR \[[@r91]\]. Chicken PR contains four Ser-Pro phosphorylation sites \[[@r32]; [@r84]\] and all are in the regions common to the PR-B and PR-A isoforms. In contrast, human PR is highly phosphorylated. There are a number of phosphorylation sites common to the PR-A and PR-B isoforms, but PR-B contains at least four additional phosphorylation sites in its unique amino-terminus \[[@r56]\]. Although Ser^294^ is in the primary sequence of both PR-A and PR-B, studies with a phosphorylation site-specific antibody reveal that Ser^294^ is phosphorylated only in the PR-B isoform \[[@r25]\]. The two isoforms have different biological activities and this difference may reflect unique conformations in the amino-termini of the two isoforms; alternatively, a protein may bind to the PR-A isoform, thereby occluding the site.

In addition to the Ser/Thr-Pro sites, sites in other consensus sequences have been identified. Additional receptor sites include Ser^167^ in ERα, a casein kinase II consensus site \[[@r7]\] that is also phosphorylated by Rsk \[[@r53]\], as well as by Akt \[[@r96]\], and a site in PR (Ser^81^), which is in a consensus CKII site and can be phosphorylated by CKII *in vitro* \[[@r118]\]. Additional sites are detected when specific cell signaling pathways are activated. For example, activation of p38 MAPK causes phosphorylation of Thr^311^ in ERα \[[@r63]\] and activation of Protein Kinase A (PKA) induces phosphorylation of Ser^305^ in ERα \[[@r5]\]. In cells with high Akt activity, AR Ser^213^ is phosphorylated in response to DHT (dihydrotestosterone); this phosphorylation is inhibited by the PI-3K inhibitor, LY294002, suggesting that the phosphorylation is Akt-dependent \[[@r102]\]. In addition to the Ser/Thr phosphorylation sites in steroid receptors, there is limited evidence to support tyrosine phosphorylation. In ERα, phosphorylation of Tyr^537^ in the hormone binding domain has been described, although others have not detected phosphorylation of this site, suggesting that the stoichiometry of phosphorylation may be low and/or it is only phosphorylated under specific conditions \[[@r4]; [@r8]\]. Two recent studies have shown that Src can phosphorylate AR on Tyr^534^ in the amino-terminus of AR and there is some evidence that other tyrosines can be phosphorylated to a lesser extent \[[@r48]; [@r57]\]. Consistent with the failure to detect tyrosine phosphorylation of AR previously, an analysis of AR in LNCaP cells revealed that tyrosine phosphorylation in response to hormone was a rapid and transient event. Using a phosphorylation site-specific antibody, Guo et al. have shown that the site is phosphorylated in AR in prostate tumors \[[@r48]\].

Applications of phosphorylation site-specific antibodies
--------------------------------------------------------

Because each receptor is multiply phosphorylated, identifying the kinases that phosphorylate the individual sites *in vivo* has been challenging. Site-specific antibodies have been made for a number of the sites and some are now commercially available. Studies with these antibodies reveal that some sites are targets for multiple kinases, allowing the receptors to respond to a variety of stimuli. For example, Ser^118^ in ERα is phosphorylated by p42/p44 MAPK as a result of EGF treatment, but cyclin H/Cdk7 phosphorylates the site in response to hormone treatment \[[@r19]; [@r20]\]. Similarly, p42/p44 MAPK phosphorylates Ser^294^ in PR-B in response to EGF, but hormone-dependent phosphorylation of the site occurs despite blocking p42/p44 MAPK activation \[[@r79]\].

Site-specific antibodies have also been useful in resolving whether candidate sites are authentic *in vivo* sites. Initial studies in LNCaP prostate cancer cells failed to identify Ser^213^, a consensus Akt phosphorylation site in AR, as an authentic *in vivo* phosphorylation site \[[@r44]\]; however, Ser^213^ is phosphorylated by Akt *in vitro* \[[@r67]\]. Subsequent studies with a site-specific antibody revealed that Ser^213^ is phosphorylated in wild type AR, but in a cell type-specific manner \[[@r102]\]. Interestingly, Ser^213^ is phosphorylated in AR in LAPC-4 prostate cancer cells. The LNCaP AR contains an amino acid mutation in the ligand binding domain (T877A). Surprisingly, when wild type and mutant ARs were expressed by transient transfection, the wild type receptor displayed much more Ser^213^ phosphorylation than did the mutant \[[@r102]\]. Thus, the AR in LNCaP cells likely is minimally phosphorylated on this site, consistent with a failure to detect phosphorylation by direct analyses of phosphopeptides.

Phosphorylation site-specific antibodies to phosphorylated Ser^118^ and Ser^167^ in ERα have been used to examine breast cancer specimens. Some studies show a correlation between phosphorylation of Ser^118^ and a favorable response to Tamoxifen \[[@r76]\], as well as a correlation between Ser^167^ phosphorylation and response to endocrine therapy \[[@r114]\]. The studies to date are limited and not all studies have found such correlations (reviewed in \[[@r77]\]). Phosphorylation of Ser^118^ also correlated with PR expression, suggesting that the phosphorylation is an indication that the ERα is active in those samples and that an ERα antagonist is likely to be beneficial.

Phosphorylation and receptor function
=====================================

Transcriptional activation
--------------------------

Initially, studies of the role of phosphorylation in receptor function were limited to measuring transcriptional activity of transiently transfected reporters. More recent studies have revealed that receptor phosphorylation contributes to a variety of functions including receptor stability, nuclear localization, transcriptional activity, interaction with coregulators, and other activities such as splicing. In some cases, the phosphorylation may determine whether a subsequent posttranslational modification will occur. As better assays are developed, it is probable that additional functions will be identified.

Using transient transfection assays to measure the activities of wild type and mutant receptors, Bai and Weigel found that an amino-terminal site in chicken PR (Ser^211^) was required for optimal transcriptional activity and that the hinge site was required for response to low levels of hormone \[[@r10]; [@r11]\]. Analyses of human PR phosphorylation site mutants revealed modest reductions in transcriptional activity \[[@r101]\]. In contrast, an Ala^294^ PR-B mutant stably transfected into a PR-negative breast cancer cell line was much less active than the corresponding line containing a stably transfected wild type receptor, suggesting that cell context and/or stable rather than transient transfection alters responsiveness \[[@r29]; [@r87]\]. Transient transfection assays of the activities of ERα and AR phosphorylation mutants also revealed some decreases in activity \[[@r64]; [@r121]\].

Additional roles for receptor phosphorylation
---------------------------------------------

Analyses of individual receptor functions have revealed more specific roles for phosphorylation. Mutation of the phosphorylation sites in GR increases receptor stability \[[@r108]\]. A GR-interacting protein, TSG101, preferentially interacts with hypophosphorylated GR and protects it from degradation \[[@r52]\]. Substitution of an alanine for Ser^294^ in human PR increases receptor stability. PR is degraded by the proteasome pathway and elimination of the phosphorylation site decreases ubiquitination of PR, suggesting that the phosphorylation may serve as a signal for ubiquitination \[[@r61]\]. In ERβ, phosphorylation of Ser^16^ enhances ER degradation \[[@r22]\]. This serine is also a site for O-GlcNAc modification \[[@r22]; [@r23]\]. The competing modifications likely regulate the stability of ERβ.

Phosphorylation can enhance or inhibit protein/protein interactions. For example, phosphorylations in the amino terminus of ERβ induced by p42/p44 MAPK enhance SRC-1 association and induce ligand-independent activation \[[@r104]\]. In contrast, activation of Akt reduces interaction between ERβ and CBP. Mutation of Ser^255^ in ERβ restores CBP binding and blocks inhibition of ERβ activity by this signaling pathway \[[@r94]\].

Phosphorylation also plays a role in regulating nuclear localization of receptors. Phosphorylation of Thr^311^ in ERα increases nuclear localization \[[@r63]\]. In contrast, stress kinase-induced phosphorylation of Ser^650^ in AR enhances cytoplasmic localization \[[@r43]\]. Phosphorylation of Ser^294^ is required for EGF-induced nuclear localization of human PR-B, but not for hormone-dependent nuclear localization \[[@r88]\]. Phosphatase activity is also required for GR relocalization to the nucleus, although the target of the phosphatase is unknown \[[@r30]; [@r41]\]. Thus, phosphorylation plays a role in subcellular distribution of most of the steroid receptors.

Phosphorylation and ERα function
--------------------------------

The role of phosphorylation in the regulation of receptor functions has been most extensively characterized for ERα and these studies highlight the wide range of kinases that can phosphorylate a receptor and the diverse roles for phosphorylation in regulating receptor function. Eight phosphorylation sites in ERα (serines 104, 106, 118, 167, 236, and 305, Thr311 and Tyr537), distributed throughout the receptor (see [Figure 2](#fig2){ref-type="fig"}), have been identified and antibodies have been prepared to study their phosphorylation \[[@r4]\]. Phosphorylation of serines 104, 106, and 118 has been implicated in optimal interaction with several coactivators \[[@r33]; [@r65]\].

Phosphorylation of Ser^118^ appears to be particularly important for physical and/or functional interactions with a variety of coregulators. It has been implicated in the interaction with (SF)3a p120, a splicing factor, and the potentiation of splicing \[[@r72]\]. On the other hand, phosphorylation of this site enhances interaction with the estrogen receptor repressor SPBP (stromelysin-1 platelet-derived growth factor-responsive element-binding protein) \[[@r42]\]. Ser^167^ phosphorylation plays a role in optimal DNA binding *in vitro* and in binding to endogenous promoters *in vivo* \[[@r17]; [@r65]; [@r96]\]. Ser^236^ phosphorylation has been implicated in inhibition of hormone-independent dimerization and DNA binding, but this inhibition is overcome by the addition of estradiol \[[@r18]\]. Phosphorylation of Ser^305^ increases transcriptional activity and has been implicated in preventing acetylation of Lys^303^ \[[@r27]\].

Interestingly, Lys^303^ is often mutated to Arg in breast cancer and this mutation has been associated with hypersensitivity to estrogen \[[@r40]\]. As discussed above, phosphorylation of Thr^311^ enhances nuclear translocation \[[@r63]\]. The role of phosphorylation of Tyr^537^ has been controversial \[[@r115]\]. Mutation of the site alters estradiol binding kinetics and some amino acid substitutions promote hormone-independent activation \[[@r109]\]. However, these changes may not be a reflection of the phosphorylation states. *In vitro* phosphorylation with Src, which phosphorylates Tyr^537^, as well as at least one other tyrosine, enhances affinity for estradiol \[[@r65]\]. As more sophisticated means of measuring receptor functions are developed, it is likely that additional roles for site-specific receptor phosphorylation will be identified.

Activation of cell signaling pathways by steroid hormones
=========================================================

There is abundant evidence that steroids can activate a variety of cell signaling pathways that influence transcription and enzyme activities independent of the genomic activities of the receptors \[[@r107]\] and, as discussed above, these pathways also modulate receptor function. These actions are mediated by steroid receptor family members, as well as by other proteins that respond to steroids. A detailed discussion of this aspect of steroid action is beyond the scope of this review. However, these pathways offer a potential means of autoregulation of the transcriptional activity of the receptors. For example, AR and ER interact with Src and MNAR (modulator of nongenomic actions of the estrogen receptor) \[[@r49]; [@r111]\]. Hormone binding results in activation of Src and the downstream activation of p42/p44 MAPK, kinases that regulate receptor function through phosphorylation of coactivators and, in some cases, phosphorylation of the receptors themselves. PR directly interacts with Src family tyrosine kinases through a proline-rich motif in the NTD of PR, which also activates a kinase cascade \[[@r15]\]. PR also induces long term activation of p42/p44 MAPK through induction of Wnt-1 and the resulting activation of the EGF receptor \[[@r36]\].

Summary
=======

Cell signaling pathways that regulate phosphorylation of steroid receptors and their coactivators are critical factors in determining the activities of steroid receptors under different physiological conditions. While many of the phosphorylation sites in the steroid receptors and some of the sites in the coregulators have been identified, others are still unknown. In particular, there are likely to be sites that are phosphorylated only in response to a specific signaling pathway; these phosphorylations may be transient, but important for specific biological responses. A number of additional candidate sites have been identified by *in vitro* phosphorylation studies. Some of these sites likely are authentic targets under some circumstances, while others may be artifacts of the conditions (high concentrations of purified receptor and kinase with no competing substrates) and are not authentic *in vivo* phosphorylation sites. Moreover, because phosphorylation studies using high specific activity γ\[^32^P\] ATP can yield a substantial signal despite a low percent or stoichiometry for the phosphorylation, some signals may be due to phosphorylation of a small amount of denatured receptor. The sites shown in [Figure 2](#fig2){ref-type="fig"} are restricted to those that have been shown to be phosphorylated in receptors expressed in mammalian or insect cells. As additional antibodies are generated for candidate sites, it is likely that others will be established as genuine sites.

Some sites are targets of multiple kinases, thereby permitting integration of signals from multiple pathways. Studies under special conditions (for example, serum-free medium or activation of a kinase pathway through a stress signal) can identify a pathway or kinase capable of phosphorylating a specific site, but these experiments should be interpreted with caution. Under other circumstances, another kinase may be the dominant regulator of the site. Although roles for some phosphorylation sites have been identified, many others have not been characterized. Roles for specific sites may also be context-dependent. This is suggested by the role of Ser^118^ not only in recruiting proteins that contribute to ERα activation, but also in the recruitment of a repressor of ERα activity. It is likely that there are phosphorylation "codes" dependent upon the signaling pathways activated under a specific physiological condition that determine the function of the receptor. These alterations will determine the phosphorylation of specific subsets of receptor phosphorylation sites, as well as the level of phosphorylation of coregulators.

While some functions may depend upon a single phosphorylation, others will have more complex requirements. For example, EGF-dependent activation of ERα requires Ser^118^ phosphorylation \[[@r16]\]; although substitution of a negatively-charged glutamic acid restores responsiveness to EGF, the Glu^118^ mutant is not constitutively active. Therefore, at least one additional EGF-induced modification of receptor or other proteins is required. In the case of AR, mutation of Ser^650^ in the hinge region of AR has been reported to reduce AR transcriptional activity by about 30% \[[@r121]\], but this site is also the target of JNK phosphorylation \[[@r43]\] and in the context of activated JNK, phosphorylation of this site reduces AR activity. As better assays for individual receptor functions are devised and more phosphorylation site-specific antibodies for receptors and coregulators are developed, it is likely that many additional roles for phosphorylation in receptor function will be identified.

Studies of the regulation of endogenous target genes by phosphorylation site mutants are likely to reveal target- and perhaps tissue-specific requirements for phosphorylations. In contrast to simple transiently transfected reporters with multiple hormone response elements, natural targets require receptor interactions with a variety of other transcription factors and coregulators to appropriately modify chromatin and induce transcription. The contributions of individual phosphorylation sites to overall biological function can be tested for conserved sites by generating mice with individual amino acid substitutions and examining their phenotypes. There is evidence that many, but not all, phosphorylation sites are conserved. Thus, differential phosphorylation is also a potential regulator of species-specific actions of receptors.
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:   amplified in breast cancer 1

AR

:   androgen receptor

CBP

:   CREB (cyclic AMP response element binding protein) binding protein

Cdk2

:   cyclin-dependent kinase 2

ChIP

:   chromatin immunoprecipitation

cPR

:   chicken progesterone receptor

DBD

:   DNA binding domain

DHT

:   dihydrotestosterone

EGF

:   epidermal growth factor

ERα

:   estrogen receptor α

ERβ

:   estrogen receptor β

GR

:   glucocorticoid receptor

GRIP1

:   (glucocorticoid receptor interacting protein 1)

GSK3β

:   (glycogen synthase kinase 3 β)

HER2

:   human epidermal growth factor receptor 2

HRE

:   hormone response element

IκK

:   IκB kinase

JNK

:   jun N terminal kinase

KGF
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LBD

:   ligand binding domain

MAPK

:   mitogen-activated protein kinase

MEKK1

:   MEK kinase 1

MMTV

:   mouse mammary tumor-like virus

MNAR

:   modulator of nongenomic action of estrogen receptor

N-CoR

:   nuclear receptor corepressor

NTD

:   amino terminal domains

Pol II

:   polymerase II

PP5

:   protein phosphatase 5

PPM1D

:   p53-induced serine/threonine phosphatase, protein phosphatase 1D magnesium-dependent, delta isoforms

PR

:   progesterone receptor

PSA

:   prostate specific antigen

SMRT

:   silencing mediator of retinoid and thyroid hormone receptors

SPBP

:   stromelysin-1 platelet-derived growth factor-responsive element-binding protein

SRC-1

:   steroid receptor coactivator-1

TIF2

:   transcription intermediary factor 2

TRAP220

:   thyroid receptor associated protein 220
